Literature DB >> 19270265

HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Sophie Lambert1, Manuella Bouttier, Roger Vassy, Michel Seigneuret, Cari Petrow-Sadowski, Sébastien Janvier, Nikolaus Heveker, Francis W Ruscetti, Gérard Perret, Kathryn S Jones, Claudine Pique.   

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) entry involves the interaction between the surface (SU) subunit of the Env proteins and cellular receptor(s). Previously, our laboratories demonstrated that heparan sulfate proteoglycans (HSPGs) and neuropilin-1 (NRP-1), a receptor of VEGF(165), are essential for HTLV-1 entry. Here we investigated whether, as when binding VEGF(165), HSPGs and NRP-1 work in concert during HTLV-1 entry. VEGF(165) binds to the b domain of NRP-1 through both HSPG-dependent and -independent interactions, the latter involving its exon 8. We show that VEGF(165) is a selective competitor of HTLV-1 entry and that HTLV-1 mimics VEGF(165) to recruit HSPGs and NRP-1: (1) the NRP-1 b domain is required for HTLV-1 binding; (2) SU binding to target cells is blocked by the HSPG-binding domain of VEGF(165); (3) the formation of Env/NRP-1 complexes is enhanced by HSPGs; and (4) the HTLV SU contains a motif homologous to VEGF(165) exon 8. This motif directly binds to NRP-1 and is essential for HTLV-1 binding to, internalization into, and infection of CD4(+) T cells and dendritic cells. These findings demonstrate that HSPGs and NRP-1 function as HTLV-1 receptors in a cooperative manner and reveal an unexpected mimicry mechanism that may have major implications in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270265      PMCID: PMC2686187          DOI: 10.1182/blood-2008-04-150342

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.

Authors:  Nicolas Manel; Felix J Kim; Sandrina Kinet; Naomi Taylor; Marc Sitbon; Jean-Luc Battini
Journal:  Cell       Date:  2003-11-14       Impact factor: 41.582

2.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules.

Authors:  H Gitay-Goren; S Soker; I Vlodavsky; G Neufeld
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

3.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

Authors:  M R Freeman; F X Schneck; M L Gagnon; C Corless; S Soker; K Niknejad; G E Peoples; M Klagsbrun
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

4.  Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.

Authors:  S Soker; H Fidder; G Neufeld; M Klagsbrun
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

5.  In vivo infection of human T-cell leukemia virus type I in non-T cells.

Authors:  Y Koyanagi; Y Itoyama; N Nakamura; K Takamatsu; J Kira; T Iwamasa; I Goto; N Yamamoto
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

Review 6.  The roles of enzyme localisation and complex formation in glycan assembly within the Golgi apparatus.

Authors:  Christopher L de Graffenried; Carolyn R Bertozzi
Journal:  Curr Opin Cell Biol       Date:  2004-08       Impact factor: 8.382

7.  Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation.

Authors:  C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I.

Authors:  Y Inoue; N Kuroda; H Shiraki; H Sato; Y Maeda
Journal:  Int J Cancer       Date:  1992-12-02       Impact factor: 7.396

10.  Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation.

Authors:  S E Macatonia; J K Cruickshank; P Rudge; S C Knight
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

View more
  55 in total

Review 1.  Molecular mechanisms of HTLV-1 infection and pathogenesis.

Authors:  Junichiro Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2011-09-28       Impact factor: 2.490

Review 2.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

3.  NF-κB inhibition facilitates the establishment of cell lines that chronically produce human T-lymphotropic virus type 1 viral particles.

Authors:  Muhammad Atif Zahoor; Subha Philip; Huijun Zhi; Chou-Zen Giam
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin.

Authors:  Matthew W Parker; Lance M Hellman; Ping Xu; Michael G Fried; Craig W Vander Kooi
Journal:  Biochemistry       Date:  2010-05-18       Impact factor: 3.162

5.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

6.  Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema.

Authors:  Akrit Sodhi; Tao Ma; Deepak Menon; Monika Deshpande; Kathleen Jee; Aumreetam Dinabandhu; Jordan Vancel; Daoyuan Lu; Silvia Montaner
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

7.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Olivier M Girard; Douglas Hanahan; Robert F Mattrey; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  Genome-wide identification of susceptibility alleles for viral infections through a population genetics approach.

Authors:  Matteo Fumagalli; Uberto Pozzoli; Rachele Cagliani; Giacomo P Comi; Nereo Bresolin; Mario Clerici; Manuela Sironi
Journal:  PLoS Genet       Date:  2010-02-19       Impact factor: 5.917

9.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  The 14th International Conference on Human Retrovirology: HTLV and related retroviruses (July 1-4, 2009; Salvador, Brazil).

Authors:  Luc Willems
Journal:  Retrovirology       Date:  2009-08-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.